HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neutrogena Should Tailor Anti-Cellulite Ad Ingredient Claims – NAD

This article was originally published in The Rose Sheet

Executive Summary

Neutrogena should modify ingredient claims in advertising for its Anti-Cellulite Treatment to "more directly speak to the formulation of the product" rather than performance of specific ingredients, the National Advertising Division of the Council for Better Business Bureaus said in a recent report

You may also be interested in...



NAD Takes Initiative In Reviews Of Anti-Aging, Cellulite Claims In 2004

Skin care marketers are likely to step up challenges to competitors' ad claims regarding wrinkle reduction as the market for anti-aging products grows, according to David Mallen, Assistant Director and Senior Attorney at the National Advertising Division of the Council of Better Business Bureaus

NAD Takes Initiative In Reviews Of Anti-Aging, Cellulite Claims In 2004

Skin care marketers are likely to step up challenges to competitors' ad claims regarding wrinkle reduction as the market for anti-aging products grows, according to David Mallen, Assistant Director and Senior Attorney at the National Advertising Division of the Council of Better Business Bureaus

FDA Draws The Line On Wrinkle Reduction Claims In Warning Letter

Wrinkle reduction claims for University Medical Products' Face Lift Collagen 5 products reflect changes to the structure or function of the body, necessitating new drug approval for the products, FDA states in a 1warning letter recently posted to its Web site

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel